Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA, 02215, USA,
J Cancer Res Clin Oncol. 2013 Oct;139(10):1701-7. doi: 10.1007/s00432-013-1491-4. Epub 2013 Aug 23.
The incidence of hot flashes under hormone manipulation therapy is so high that this symptom caused by sex hormone blocking agents has been bothering patients and has a negative impact on their quality of life. Venlafaxine and gabapentin are most promising novel nonestrogenic agents to control the symptom. We seek to quatitatively summarize the efficacy of these novel agents.
We conducted a meta-analysis of randomized controlled studies on the efficacy of venlafaxine/gabapentin to hot flashes in cancer patient under hormone deprivation therapies. A search for Medline, Embase, Cochrane Central Register of Controlled Trials, Ichushi, and Google Scholar yielded 733 citations, which were independently assessed by two authors. We estimated overall effect sizes and its 95 % confidence intervals (CI) for the efficacy of these agents compared with the controls with standardized mean difference.
A total of 5 studies involving 588 cancer patients with hot flashes finally fulfilled the predefined inclusion criteria. Overall effect size of the efficacy of venlafaxine/gabapentin was -0.630 (95 % CI [-0.801, -0.459]).
Venlafaxine/gabapentin significantly improved hot flashes in cancer patients under hormone manipulation therapies.
激素治疗下热潮红的发生率如此之高，以至于这种由性激素阻断剂引起的症状一直困扰着患者，并对其生活质量产生负面影响。文拉法辛和加巴喷丁是最有前途的新型非雌激素类药物，可以控制这种症状。我们旨在定量总结这些新型药物的疗效。
我们对激素剥夺治疗下癌症患者使用文拉法辛/加巴喷丁治疗热潮红的随机对照研究进行了荟萃分析。在 Medline、Embase、Cochrane 对照试验中心注册库、Ichushi 和 Google Scholar 上进行了检索，共得到 733 条引文，由两位作者独立评估。我们使用标准化均数差来估计这些药物与对照组相比的总体疗效的效应大小及其 95%置信区间（CI）。
共有 5 项研究纳入了 588 名有热潮红的癌症患者，最终符合预先设定的纳入标准。文拉法辛/加巴喷丁疗效的总体效应大小为-0.630（95%CI[-0.801，-0.459]）。
文拉法辛/加巴喷丁可显著改善激素治疗下的癌症患者的热潮红。
